The PennZone

  • Home
  • Non-profit
  • Music
  • Books
  • Entertainment
  • Marketing
  • Legal
  • Health
  • Food

Enterin Announces Appointment of New CEO
The PennZone/10088808

Trending...
  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
  • Badanamu Partners With Moonbug Entertainment In Landmark Distribution Deal
  • Mad Darbarian is available for views as a Horror Host
PHILADELPHIA, Oct. 16, 2020 /PRNewswire/ -- Enterin, Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, announces the appointment of David McCullough as Chief Executive Officer.

With over 30 years of pharma/biotech experience, Mr. McCullough is a demonstrated strategic, creative, and accomplished leader. With executive and board director experience in startup and established companies, David brings expertise in both the private and public sector. He has a deep understanding of drug development, clinical and regulatory strategy, commercial, finance, IP, manufacturing and operations. Mr. McCullough has a proven track record of building highly skilled, energetic, cross-functional teams both domestically and globally. He has strong experience moving products from early development to launch, including orphan drugs and billion-dollar brands. At Merck, he played a lead role in the $13.5B acquisition of Serono Biotech, and he was honored by the Merck family as a top contributor in corporate development. Additionally, Mr. McCullough has held leadership positions in Allergopharma/EMD Serono and BioCryst. He is interested in Enterin as he has a personal passion for the neurodegenerative therapeutic area and the patient population that can be served with better therapeutic outcomes. "I am thrilled to have the opportunity to join this team that is pioneering the science behind truly innovative approaches in the treatment of neurodegenerative diseases," says McCullough.

More on The PennZone
  • American Garden Rose Selections™ Announces 2027 Winners
  • Crossroads4Hope Launches Blood Cancer Resource Hub
  • Wilson Venture Capital to Launch News Organization; Will Name Trevor Wilson CEO
  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • Georgia's Magical Nights of Lights Bigger and Brighter for 2026

Enterin's founders and chairmen, Michael Zasloff, MD, PhD and Denise Barbut MD, FRCP reciprocated the sentiment. They said, "We are delighted that David has agreed to join Enterin. His extensive experience in the pharmaceutical industry will supplement the scientific and medical expertise of the existing management team."

About Enterin Inc.

Enterin Inc. is the first company to develop novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. Enterin Inc. is now progressing ENT-01 through clinical trials in an attempt to reverse the neurologic symptoms of Parkinson's disease.

More on The PennZone
  • Bicentennial Occult Outing Alternative History Video Series Launches for Spooky Season
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
  • Tampa Bay Reporter Launches with a Mission to Deliver Local News with National Reach

For more information, please visit www.enterininc.com.

Contact
Enterin Inc.
[email protected]

Related Images

enterin-logo.jpg
Enterin Logo

SOURCE Enterin Inc.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Top 100 Golf Coach Daniel Guest and Imagen Golf Announce Partnership with Remo Golf at Fairways Golf Club
  • DBF Viewer 2000 v9.32 Adds New Control for Data Export
  • Badanamu Partners With Moonbug Entertainment In Landmark Distribution Deal
  • Exonerated Movers Launches in Philadelphia on International Wrongful Conviction Day
  • Atlas Advisors President and Founder Mike McGuire Named a 2026 Leader in Business and Finance by LVB
  • Client 1st Financial Founder Michael Fischer Recognized for Building a Relationship-Rooted Career
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single
  • Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
  • Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
  • Mad Darbarian is available for views as a Horror Host
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
  • Derek Cook's Roofing Encourages Homeowners to Prepare for Fall Weather
  • Boston Industrial Solutions Expands Product Offering with Pad Printing Pads and Silicone for Custom Pad Manufacturing
  • Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP
  • Phoenix 5/7 Emerges as a Genre-Fluid Artist Collective
  • Massage Revolution Expands to Santa Monica With New Wilshire Boulevard Location
  • "Warrior Defined" Event Brings Men Together in Charlotte, With Calls for Events Across the U.S

Popular on PennZone

  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!
  • Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
  • Lake Norman Philharmonic - Free Community Concert
  • Mandeville Pests May Pose Serious Health Risks for Your Family
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Paul Ohana - From Beverly Hills Salon Chair To Beauty Founder Celebrity Hair Expert
  • STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • New Bethany's 35th Annual Souper Day to Spotlight Connection Between Health, Hunger and Housing

Similar on PennZone

  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • Genuine Hospitality, LLC Selected to Operate Fairfield Inn & Suites Tampa Wesley Chapel
  • Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
  • HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us